DBV Technologies (DBVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DBV Technologies (DBVT) has a cash flow conversion efficiency ratio of -0.209x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.19 Million) by net assets ($168.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DBV Technologies (DBVT) balance sheet quality index to measure how much of total assets are equity-financed.
DBV Technologies - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how DBV Technologies's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore DBV Technologies long-term investment allocation to see how much of total assets are deployed in long-term investments.
DBV Technologies Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DBV Technologies ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen AV-Display Co. Ltd.
SHE:300939
|
0.017x |
|
Asseco Business Solutions S.A.
WAR:ABS
|
0.101x |
|
Shenzhen Urovo Technology Co Ltd
SHE:300531
|
0.058x |
|
HMT Limited
NSE:HMT
|
-0.004x |
|
Ningbo Cixing
SHE:300307
|
-0.015x |
|
Silicon Integrated Systems Corp
TW:2363
|
-0.001x |
|
Sgis Songshan Co Ltd
SHE:000717
|
0.093x |
|
Navient Corp
NASDAQ:NAVI
|
0.073x |
Annual Cash Flow Conversion Efficiency for DBV Technologies (2011–2025)
The table below shows the annual cash flow conversion efficiency of DBV Technologies from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see DBVT market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $168.77 Million | $-121.18 Million | -0.718x | +81.18% |
| 2024-12-31 | $27.39 Million | $-104.47 Million | -3.815x | -571.38% |
| 2023-12-31 | $140.19 Million | $-79.65 Million | -0.568x | -98.36% |
| 2022-12-31 | $194.45 Million | $-55.70 Million | -0.286x | +73.79% |
| 2021-12-31 | $99.03 Million | $-108.24 Million | -1.093x | -35.63% |
| 2020-12-31 | $205.49 Million | $-165.61 Million | -0.806x | -4.95% |
| 2019-12-31 | $193.19 Million | $-148.35 Million | -0.768x | +31.83% |
| 2018-12-31 | $165.78 Million | $-186.74 Million | -1.126x | -28.02% |
| 2017-12-31 | $182.88 Million | $-160.91 Million | -0.880x | -258.89% |
| 2016-12-31 | $267.90 Million | $-65.68 Million | -0.245x | -195.04% |
| 2015-12-31 | $384.24 Million | $-31.93 Million | -0.083x | +53.34% |
| 2014-12-31 | $182.22 Million | $-32.45 Million | -0.178x | +45.72% |
| 2013-12-31 | $74.09 Million | $-24.31 Million | -0.328x | -23.20% |
| 2012-12-31 | $66.84 Million | $-17.80 Million | -0.266x | +49.14% |
| 2011-12-31 | $19.79 Million | $-10.36 Million | -0.524x | -- |
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of i… Read more